High dose methylprednisolone and rituximab is an effective therapy in advanced refractory chronic lymphocytic leukemia resistant to fludarabine therapy. [electronic resource]
Producer: 20080703Description: 475-6 p. digitalISSN:- 1592-8721
- Adult
- Aged
- Antibodies, Monoclonal -- adverse effects
- Antibodies, Monoclonal, Murine-Derived
- Antimetabolites, Antineoplastic -- administration & dosage
- Antineoplastic Agents -- adverse effects
- Antineoplastic Combined Chemotherapy Protocols -- therapeutic use
- Combined Modality Therapy
- Disease-Free Survival
- Drug Resistance, Neoplasm
- Female
- Humans
- Immunotherapy -- adverse effects
- Infection Control
- Infections -- etiology
- Leukemia, Lymphocytic, Chronic, B-Cell -- drug therapy
- Male
- Methylprednisolone -- adverse effects
- Middle Aged
- Rituximab
- Salvage Therapy
- Vidarabine -- administration & dosage
No physical items for this record
Publication Type: Clinical Trial; Controlled Clinical Trial; Letter
There are no comments on this title.
Log in to your account to post a comment.